Roman Perez-Soler, MD, talks about NSCLC tumors becoming resistance to chemotherapy and first-line treatment.
Roman Perez-Soler, MD, chairman and chief, department of medical oncology, Montefiore Medical Center, deputy director, Albert Einstein Cancer Center, talks about non-small cell lung cancer (NSCLC) tumors becoming resistant to chemotherapy and first-line treatment.
Perez-Soler says that usually NSCLC tumors become resistant within 2 to 3 months, or grow back with a resistance to the same drug initially used as treatment. He adds that once that occurs, it could be time to switch to immunotherapies, which he believes could also be an effective front-line treatment by themselves or with chemotherapies due to their low toxicities.
Ornstein Advises on Starting Dose and Management of Lenvatinib in RCC
April 21st 2024During a Case-Based Roundtable® event, Moshe Ornstein, MD, MA, provided guidance on dosing and toxicity concerns in a patient treated with lenvatinib plus pembrolizumab for advanced renal cell carcinoma.
Read More